$30.05
-2.1%MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Chief Executive Officer, President & Director
Compensation
$788,300
Chief Financial Officer
Compensation
$642,001
Chief Human Resources Officer
Chief Medical Officer
Compensation
$520,512
Senior Vice President of Discovery & Non-Clinical Development
Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls
Senior Vice President of Regulatory & Quality
Vice President of Marketing
During the last 12 months, insiders have purchased $16.13M and sold $2.14M worth of MBX shares, resulting in $14.00M of net buying activity.
18.5K
525.66K
55.8K
2.14M
-1.6M
-$1.61M
0
0.00
0
0.00
+0
+$0
989.5K
15.61M
0
0.00
+15.6M
+$15.61M
0
0.00
0
0.00
+0
+$0
Heron Patrick J
Director, 10 Percent Owner:
$12.00M
Hoerter Steven L.
Director
$2.74M
Hawryluk P. Kent
Director, Officer: President & Ceo
$1.39M
Azoulay Salomon
Officer: Chief Medical Officer
$2.12M
Hawryluk P. Kent
Director, Officer: President & Ceo
$18K
Strong bullish signal with $14.00M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
3 insider buyers vs. 2 sellers. More insiders buying than selling indicates positive sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
MBX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | April 22, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.